search
Back to results

Reduction of the Metabolic Syndrome in Navarra-Spain (RESMENA-S)

Primary Purpose

Metabolic Syndrome, Obesity, Diabetes

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Crononutrition
American Heart Association
Sponsored by
Clinica Universidad de Navarra, Universidad de Navarra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Metabolic syndrome, Oxidative stress, Proinflammatory state, Insulin resistance, Hypertension, Dyslipidemia, Mediterranean diet, Glycemic index, Hypocaloric diet, Hyperproteic diet, Macronutrient distribution, Antioxidant capacity of the diet, Crononutrition, Dietary and psychological support, Waist circumference

Eligibility Criteria

35 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 35-70 years old
  • Both sexes: Male and Female
  • Metabolic Syndrome according to the IDF(2005)criteria:

Waist circumference cutoffs (male ≥94 cm or female ≥80 cm) plus any two of the following four factors:

  1. Fasting glucose ≥5.55 mmol/L or use of antidiabetic medication
  2. Systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or use of antihypertensive medication
  3. Fasting triglycerides ≥1.7 mm/L; and HDL-C <1.0 mm/L in men and <1.3 mm/L in women or specific treatment for this lipid abnormality

Exclusion Criteria:

  • Recent follow-up of diets designed for weight loss
  • Unstable weight in the past 3 months
  • Alcoholic and drug dependence
  • Hormonal treatment
  • No stable pharmacological treatment
  • Eating-disordered behaviors
  • Severe physical or mental disability
  • Pregnancy
  • Terminal disease
  • Institutionalization

Sites / Locations

  • University of Navarra

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Crononutrition

American Heart Association

Arm Description

Dietary pattern: Personalized diet Caloric restriction (-30% Total energy intake) High adherence to the Mediterranean Diet Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat) Low glycemic index/load Increased antioxidant capacity of the diet

Dietary pattern: Personalized diet Caloric diet (-30% Total energy intake) Macronutrients distribution according to the American Heart Association (AHA) guidelines

Outcomes

Primary Outcome Measures

Body fat
Through this specific nutritional intervention program we will try to reduce the metabolic syndrome features such as waist circumference, body weight and adiposity. To evaluate the body composition, bioimpedance, DEXA and anthropometry methodology will be used at the beginning and after two months of intervention.
Lipid profile
To evaluate lipid improvements the following measurements will be taking into account: Free fatty acids Total cholesterol HDL-cholesterol LDL-cholesterol
Glucose Profile
To evaluate glucose improvements the following measurements will be taking into account: Glucose Insulin HOMA

Secondary Outcome Measures

Inflammation state
As secondary outcome some inflammatory markers will be analyzed: CRP IL-6 TNF-alpha IL-18 PAI-1 Homocystein
Oxidative stress
As secondary outcome some oxidative stress markers will be analyzed: MDA LDL-OX Total antioxidant capacity (TAC)
Psychological tests
Beck Depression Inventory Stai Trait Anxiety Inventory Mood thermometer visual analogue scale Anxiety thermometer visual analogue scale NEO personality inventory-revised test
Peripheral neurotransmitters
Dopamine Dopac Serotonin 5-Hydroxyindoleacetic acid Noradrenaline
Epigenetics
DNA methylation microRNAs expression
Fatty Liver biomarkers / Non invasive liver scoring system.
Measurements in fatty liver biomarkers: Serum transaminases (AST & ALT (U/L)), GGT (U/L) and CK18 (U/L) concentrations will be measured in a fasting state at the beginning, at 2 months and at the end of the intervention. - A specificif Fatty Liver Index was calculated at the begining, at 2 months and at the end of the intervention.

Full Information

First Posted
March 11, 2010
Last Updated
May 11, 2016
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Collaborators
Hospital of Navarra
search

1. Study Identification

Unique Protocol Identification Number
NCT01087086
Brief Title
Reduction of the Metabolic Syndrome in Navarra-Spain
Acronym
RESMENA-S
Official Title
Reduction of the Metabolic Syndrome in Navarra-Spain (RESMENA-S) Through an Innovative Multidisciplinary Strategy Based on the Crononutrition and Dietary Training Concepts, in Addition to Both Dietary and Psychological Control
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
November 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Collaborators
Hospital of Navarra

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether a dietary pattern based on crononutrition and dietary training, together with dietary and psychological control, can reduce the body weight, improve the oxidative and inflammatory state in subjects with diagnosed metabolic syndrome features and can reduce the prevalence of the Metabolic syndrome in the population.
Detailed Description
The dietary pattern that characterizes the present nutritional intervention study is based on personalized diet, by elaborating tailoring-diets for each subject regarding his energetic needs and assuring a high adherence to the Mediterranean Diet. Moreover, the diet to be performed will be a hyperproteic diet to guarantee a satiety effect and a lower recovery of the lost weight, in accordance with the results derived from the main European study about nutrition (DIOGENES). The glycemic index/load will be also controlled in the study diet. The increase of the antioxidant capacity of the diet will be increased by the intake of fruits, walnuts and virgin olive oil among other antioxidant containing foods. The present initiative, based on the traditional diet, aims to integrate the main results obtained from diverse observational epidemiological studies and interventional studies in the dietary pattern of the present study. At the same time, the study will apply the concept of crononutrition by selecting and distributing the foods thorough the day according the physiological needs of each individual. In addition to the quantitative and qualitative composition of the diet, the study will take into account other important factors such as the behavior habits regarding the food, the frequency of consumption, the size of the eating portions, the distribution of the portions along the day, the feeling of fullness, the eating speed and so on. The aforementioned factors have recently been shown to be related to the gain of weight. Other non dietary factors, such as smoking habits, sedentary life, socio-economic level, will be also controlled in the present study. Moreover, the project will integrate the dietary support together with psychological support due to the fact that the state of mind has been shown to be associated with the MS in some scientific publications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Obesity, Diabetes, Cardiovascular Disease
Keywords
Metabolic syndrome, Oxidative stress, Proinflammatory state, Insulin resistance, Hypertension, Dyslipidemia, Mediterranean diet, Glycemic index, Hypocaloric diet, Hyperproteic diet, Macronutrient distribution, Antioxidant capacity of the diet, Crononutrition, Dietary and psychological support, Waist circumference

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
109 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Crononutrition
Arm Type
Experimental
Arm Description
Dietary pattern: Personalized diet Caloric restriction (-30% Total energy intake) High adherence to the Mediterranean Diet Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat) Low glycemic index/load Increased antioxidant capacity of the diet
Arm Title
American Heart Association
Arm Type
Placebo Comparator
Arm Description
Dietary pattern: Personalized diet Caloric diet (-30% Total energy intake) Macronutrients distribution according to the American Heart Association (AHA) guidelines
Intervention Type
Behavioral
Intervention Name(s)
Crononutrition
Other Intervention Name(s)
RYTHMONUTRITION, METABOLIC SYNDROME, OBESITY, DIABETES, CARDIOVASCULAR DISEASE, RESMENA-S
Intervention Description
After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period ("autonomy phase") in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
Intervention Type
Behavioral
Intervention Name(s)
American Heart Association
Other Intervention Name(s)
RESMENA-A
Intervention Description
After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period ("autonomy phase") in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
Primary Outcome Measure Information:
Title
Body fat
Description
Through this specific nutritional intervention program we will try to reduce the metabolic syndrome features such as waist circumference, body weight and adiposity. To evaluate the body composition, bioimpedance, DEXA and anthropometry methodology will be used at the beginning and after two months of intervention.
Time Frame
One year
Title
Lipid profile
Description
To evaluate lipid improvements the following measurements will be taking into account: Free fatty acids Total cholesterol HDL-cholesterol LDL-cholesterol
Time Frame
One year
Title
Glucose Profile
Description
To evaluate glucose improvements the following measurements will be taking into account: Glucose Insulin HOMA
Time Frame
One year
Secondary Outcome Measure Information:
Title
Inflammation state
Description
As secondary outcome some inflammatory markers will be analyzed: CRP IL-6 TNF-alpha IL-18 PAI-1 Homocystein
Time Frame
One year
Title
Oxidative stress
Description
As secondary outcome some oxidative stress markers will be analyzed: MDA LDL-OX Total antioxidant capacity (TAC)
Time Frame
One year
Title
Psychological tests
Description
Beck Depression Inventory Stai Trait Anxiety Inventory Mood thermometer visual analogue scale Anxiety thermometer visual analogue scale NEO personality inventory-revised test
Time Frame
January 2010-November 2011
Title
Peripheral neurotransmitters
Description
Dopamine Dopac Serotonin 5-Hydroxyindoleacetic acid Noradrenaline
Time Frame
March-April 2013
Title
Epigenetics
Description
DNA methylation microRNAs expression
Time Frame
April 2012-July 2014
Title
Fatty Liver biomarkers / Non invasive liver scoring system.
Description
Measurements in fatty liver biomarkers: Serum transaminases (AST & ALT (U/L)), GGT (U/L) and CK18 (U/L) concentrations will be measured in a fasting state at the beginning, at 2 months and at the end of the intervention. - A specificif Fatty Liver Index was calculated at the begining, at 2 months and at the end of the intervention.
Time Frame
May 2016- January 2017

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 35-70 years old Both sexes: Male and Female Metabolic Syndrome according to the IDF(2005)criteria: Waist circumference cutoffs (male ≥94 cm or female ≥80 cm) plus any two of the following four factors: Fasting glucose ≥5.55 mmol/L or use of antidiabetic medication Systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or use of antihypertensive medication Fasting triglycerides ≥1.7 mm/L; and HDL-C <1.0 mm/L in men and <1.3 mm/L in women or specific treatment for this lipid abnormality Exclusion Criteria: Recent follow-up of diets designed for weight loss Unstable weight in the past 3 months Alcoholic and drug dependence Hormonal treatment No stable pharmacological treatment Eating-disordered behaviors Severe physical or mental disability Pregnancy Terminal disease Institutionalization
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
María Ángeles MA Zulet, PhD
Organizational Affiliation
University of Navarra
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Alfredo JA Martínez, PhD, RN
Organizational Affiliation
University of Navarra
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Itziar I Abete, PhD
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Lluis L Forga, PhD
Organizational Affiliation
Hospital of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Blanca Esther BE Martínez de Morentin, MD
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Santiago S Navas-Carretero, PhD
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Rocío R de la Iglesia, M.Sc
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Patricia P López Legarrea, M.Sc
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Isabel I Bondia-Pons, PhD
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Aurora A Perez Cornago, M.Sc
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
José Luiz JL Marques-Rocha, M.Sc
Organizational Affiliation
Universidade Federal de Viçosa
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Marcos M García-Lacarte, M.Sc
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Irene I Cantero, M.Sc
Organizational Affiliation
University of Navarra
Official's Role
Study Chair
Facility Information:
Facility Name
University of Navarra
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
19816812
Citation
Hermsdorff HH, Zulet MA, Abete I, Martinez JA. Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine. 2009 Dec;36(3):445-51. doi: 10.1007/s12020-009-9248-1.
Results Reference
background
PubMed Identifier
19783122
Citation
Puchau B, Zulet MA, de Echavarri AG, Hermsdorff HH, Martinez JA. Dietary total antioxidant capacity is negatively associated with some metabolic syndrome features in healthy young adults. Nutrition. 2010 May;26(5):534-41. doi: 10.1016/j.nut.2009.06.017. Epub 2009 Sep 26.
Results Reference
background
PubMed Identifier
19766058
Citation
Perez-Matute P, Zulet MA, Martinez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol. 2009 Dec;9(6):771-9. doi: 10.1016/j.coph.2009.08.005. Epub 2009 Sep 18.
Results Reference
background
PubMed Identifier
19656442
Citation
Toledo E, de A Carmona-Torre F, Alonso A, Puchau B, Zulet MA, Martinez JA, Martinez-Gonzalez MA. Hypothesis-oriented food patterns and incidence of hypertension: 6-year follow-up of the SUN (Seguimiento Universidad de Navarra) prospective cohort. Public Health Nutr. 2010 Mar;13(3):338-49. doi: 10.1017/S1368980009991066. Epub 2009 Aug 6.
Results Reference
background
PubMed Identifier
19457510
Citation
Sotos-Prieto M, Zulet MA, Corella D. [Scientific evidence of the mediterranean diet effects in determining intermediate and final cardiovascular disease phenotypes]. Med Clin (Barc). 2010 Jan 23;134(1):22-9. doi: 10.1016/j.medcli.2009.01.033. Epub 2009 May 19. Spanish.
Results Reference
background
PubMed Identifier
18985060
Citation
Puchau B, Zulet MA, Gonzalez de Echavarri A, Navarro-Blasco I, Martinez JA. Selenium intake reduces serum C3, an early marker of metabolic syndrome manifestations, in healthy young adults. Eur J Clin Nutr. 2009 Jul;63(7):858-64. doi: 10.1038/ejcn.2008.48. Epub 2008 Nov 5.
Results Reference
background
PubMed Identifier
17970534
Citation
Zulet MA, Puchau B, Navarro C, Marti A, Martinez JA. [Inflammatory biomarkers: the link between obesity and associated pathologies]. Nutr Hosp. 2007 Sep-Oct;22(5):511-27. Spanish.
Results Reference
background
PubMed Identifier
19079872
Citation
Abete I, Parra MD, Zulet MA, Martinez JA. Different dietary strategies for weight loss in obesity: role of energy and macronutrient content. Nutr Res Rev. 2006 Jun;19(1):5-17. doi: 10.1079/NRR2006112.
Results Reference
background
PubMed Identifier
18702949
Citation
Martinez MA, Puig JG, Mora M, Aragon R, O'Dogherty P, Anton JL, Sanchez-Villares T, Rubio JM, Rosado J, Torres R, Marcos J, Pallardo LF, Banegas JR; MAPA (Monitorizacion Ambulatoria de la Presion Arterial) Working Group. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study. Metabolism. 2008 Sep;57(9):1232-40. doi: 10.1016/j.metabol.2008.04.017.
Results Reference
background
PubMed Identifier
18753667
Citation
Sanchez-Chaparro MA, Calvo-Bonacho E, Gonzalez-Quintela A, Fernandez-Labandera C, Cabrera M, Sainz JC, Fernandez-Meseguer A, Banegas JR, Ruilope LM, Valdivielso P, Roman-Garcia J; Ibermutuamur Cardiovascular Risk Assessment (ICARIA) Study Group. Occupation-related differences in the prevalence of metabolic syndrome. Diabetes Care. 2008 Sep;31(9):1884-5. doi: 10.2337/dc08-0431. Epub 2008 Jun 20.
Results Reference
background
PubMed Identifier
19176282
Citation
Babio N, Bullo M, Basora J, Martinez-Gonzalez MA, Fernandez-Ballart J, Marquez-Sandoval F, Molina C, Salas-Salvado J; Nureta-PREDIMED Investigators. Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):563-70. doi: 10.1016/j.numecd.2008.10.007. Epub 2009 Jan 26.
Results Reference
background
PubMed Identifier
19298202
Citation
Abete I, Parra D, Martinez JA. Legume-, fish-, or high-protein-based hypocaloric diets: effects on weight loss and mitochondrial oxidation in obese men. J Med Food. 2009 Feb;12(1):100-8. doi: 10.1089/jmf.2007.0700.
Results Reference
background
PubMed Identifier
19246894
Citation
Goyenechea E, Parra D, Crujeiras AB, Abete I, Martinez JA. A nutrigenomic inflammation-related PBMC-based approach to predict the weight-loss regain in obese subjects. Ann Nutr Metab. 2009;54(1):43-51. doi: 10.1159/000205319. Epub 2009 Feb 27.
Results Reference
background
PubMed Identifier
18308431
Citation
Abete I, Parra D, Martinez JA. Energy-restricted diets based on a distinct food selection affecting the glycemic index induce different weight loss and oxidative response. Clin Nutr. 2008 Aug;27(4):545-51. doi: 10.1016/j.clnu.2008.01.005. Epub 2008 Mar 4.
Results Reference
background
PubMed Identifier
30026784
Citation
Cantero I, Abete I, Del Bas JM, Caimari A, Arola L, Zulet MA, Martinez JA. Changes in lysophospholipids and liver status after weight loss: the RESMENA study. Nutr Metab (Lond). 2018 Jul 17;15:51. doi: 10.1186/s12986-018-0288-5. eCollection 2018.
Results Reference
derived
PubMed Identifier
26197243
Citation
Garcia-Lacarte M, Milagro FI, Zulet MA, Martinez JA, Mansego ML. LINE-1 methylation levels, a biomarker of weight loss in obese subjects, are influenced by dietary antioxidant capacity. Redox Rep. 2016 Mar;21(2):67-74. doi: 10.1179/1351000215Y.0000000029. Epub 2016 Feb 15.
Results Reference
derived
PubMed Identifier
25641909
Citation
Bondia-Pons I, Martinez JA, de la Iglesia R, Lopez-Legarrea P, Poutanen K, Hanhineva K, Zulet Mde L. Effects of short- and long-term Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial. Mol Nutr Food Res. 2015 Apr;59(4):711-28. doi: 10.1002/mnfr.201400309. Epub 2015 Feb 5.
Results Reference
derived
PubMed Identifier
24762259
Citation
Perez-Cornago A, de la Iglesia R, Lopez-Legarrea P, Abete I, Navas-Carretero S, Lacunza CI, Lahortiga F, Martinez-Gonzalez MA, Martinez JA, Zulet MA. A decline in inflammation is associated with less depressive symptoms after a dietary intervention in metabolic syndrome patients: a longitudinal study. Nutr J. 2014 Apr 24;13:36. doi: 10.1186/1475-2891-13-36.
Results Reference
derived
PubMed Identifier
24567125
Citation
Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, Pardo M, Casanueva FF, Zulet MA, Martinez JA. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutr Diabetes. 2014 Feb 24;4(2):e110. doi: 10.1038/nutd.2014.7.
Results Reference
derived
PubMed Identifier
26417268
Citation
de la Iglesia R, Mansego ML, Sanchez-Muniz FJ, Zulet MA, Martinez JA. Arylesterase activity is associated with antioxidant intake and paraoxonase-1 (PON1) gene methylation in metabolic syndrome patients following an energy restricted diet. EXCLI J. 2014 Apr 9;13:416-26. eCollection 2014.
Results Reference
derived
PubMed Identifier
24314875
Citation
Perez-Cornago A, Lopez-Legarrea P, de la Iglesia R, Lahortiga F, Martinez JA, Zulet MA. Longitudinal relationship of diet and oxidative stress with depressive symptoms in patients with metabolic syndrome after following a weight loss treatment: the RESMENA project. Clin Nutr. 2014 Dec;33(6):1061-7. doi: 10.1016/j.clnu.2013.11.011. Epub 2013 Nov 22.
Results Reference
derived
PubMed Identifier
24249967
Citation
Lopez-Legarrea P, Mansego ML, Zulet MA, Martinez JA. SERPINE1, PAI-1 protein coding gene, methylation levels and epigenetic relationships with adiposity changes in obese subjects with metabolic syndrome features under dietary restriction. J Clin Biochem Nutr. 2013 Nov;53(3):139-44. doi: 10.3164/jcbn.13-54. Epub 2013 Oct 31.
Results Reference
derived
PubMed Identifier
23406163
Citation
Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martinez JA, Zulet MA. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial. Nutr Metab (Lond). 2013 Feb 13;10(1):22. doi: 10.1186/1743-7075-10-22.
Results Reference
derived
PubMed Identifier
21519726
Citation
Zulet MA, Bondia-Pons I, Abete I, de la Iglesia R, Lopez-Legarrea P, Forga L, Navas-Carretero S, Martinez JA. The reduction of the metabolyc syndrome in Navarra-Spain (RESMENA-S) study: a multidisciplinary strategy based on chrononutrition and nutritional education, together with dietetic and psychological control. Nutr Hosp. 2011 Jan-Feb;26(1):16-26.
Results Reference
derived

Learn more about this trial

Reduction of the Metabolic Syndrome in Navarra-Spain

We'll reach out to this number within 24 hrs